Request Demo
Last update 16 May 2025
MC150
Last update 16 May 2025
Overview
Basic Info
Drug Type Autologous CAR-T |
Synonyms CD19 CART cell therapy (Chongqing Precision Biotechnology Co., Ltd.), MC-1-50, MC150 |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
8
Clinical Trials associated with MC150NCT06892145
Phase I Clinical Trial of CD19-targeting Chimeric Antigen Receptor T Lymphocyte (MC-1-50) for the Treatment of Refractory Adult Systemic Lupus Erythematosus(SLE)
CTR20242431
靶向 CD19 嵌合抗原受体 T 淋巴细胞（ MC-1-50）制剂治疗成人复发/难治性 CD19 阳性 B 细胞急性淋巴细胞白血病的Ⅰ期临床研究
[Translation] Phase I clinical study of a chimeric antigen receptor T lymphocyte (MC-1-50) agent targeting CD19 in the treatment of relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia in adults
NCT06641024
Phase I Clinical Study of CD19-targeting Chimeric Antigen Receptor T Lymphocyte (MC-1-50) for the Treatment of Relapsed/Refractory CD19-positive B-cell Acute Lymphoblastic Leukemia (B-ALL)
100 Clinical Results associated with MC150
Login to view more data
100 Translational Medicine associated with MC150
Login to view more data
100 Patents (Medical) associated with MC150
Login to view more data
100 Deals associated with MC150
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | Phase 2 | China | 01 Jun 2019 | |
| Acute lymphoblastic leukemia recurrent | Phase 1 | China | 01 Nov 2024 | |
| CD19-positive B-cell acute lymphoblastic leukemia | Phase 1 | China | 01 Nov 2024 | |
| Refractory B Acute Lymphoblastic Leukemia | Phase 1 | China | 01 Nov 2024 | |
| CD19 positive B-Cell Lymphoma | Phase 1 | China | 31 Dec 2023 | |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 1 | China | 31 Aug 2023 | |
| Dermatomyositis | Phase 1 | China | 31 Aug 2023 | |
| Scleroderma, Systemic | Phase 1 | China | 31 Aug 2023 | |
| Sjogren's Syndrome | Phase 1 | China | 31 Aug 2023 | |
| Systemic Lupus Erythematosus | Phase 1 | China | 31 Aug 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 19 | nvbqpuptwr(rlirqqsoig) = rkdxftfpix mbvecsxdec (naiwzmzwiw ) View more | Positive | 26 May 2023 | |||
Phase 1/2 | 13 | ctjmxyzxao(gtdavwjxuk) = laigmsmnyy yihlfyshun (jlcfspvwkz ) View more | Positive | 26 May 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free